HK Stock MarketDetailed Quotes

01541 IMMUNEONCO-B

Watchlist
  • 5.030
  • -0.250-4.73%
Market Closed Dec 20 16:08 CST
2.05BMarket Cap-5.00P/E (TTM)

About IMMUNEONCO-B Company

Yiming Angke Biomedical Technology (Shanghai) Co., Ltd. is a scientific research-oriented biotechnology company dedicated to developing innovative cancer immunotherapy. The company was incorporated in 2015 and is one of the few biotechnology companies in the world that can systematically utilize innate immunity and adaptive immune systems. By strictly adhering to the “Drug-by-Design” concept and using our R&D platform, we have designed a rich pipeline portfolio, including more than ten innovative drug candidates and eight ongoing clinical projects. Our pipeline is based on the deep and broad asset portfolio of innate immunity, which reflects our deep understanding of cutting-edge tumor biology and immunology, as well as our expertise in turning scientific research into drug candidates.

Company Profile

Symbol01541
Company NameIMMUNEONCO-B
ISINCNE100006624
Listing DateSep 5, 2023
Issue Price18.60
Shares Offered17.15M share(s)
FoundedJun 18, 2015
Registered AddressChina
Chairmanwenzhi tian
Secretaryjianweiguanmei li
Audit InstitutionDeloitte Guan Huang Chen Fang Certified Public Accountants
Company CategoryMainland registration of Mainland Individuals control
Registered OfficeBuilding 15, Lane 1000, Zhang Heng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, China
Head Office and Principal Place of Business5th Floor, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees150
MarketHong Kong motherboard
Phone(021)38016387;(021)58356573
Emailwenzhi.tian@immuneonco.com
Websitehttp://www.immuneonco.com
Business Yiming Angke Biomedical Technology (Shanghai) Co., Ltd. is a Chinese company mainly engaged in testing biotechnology research and development. The company's main business includes developing biotechnology for systemically utilizing innate and adaptive immunity, and developing next-generation tumor immunotherapy, which focuses mainly on the adaptive immune system. The company's business covers both domestic and overseas markets.

Company Executives

  • Name
  • Position
  • Salary
  • wenzhi tian
  • Chairman, CEOs, Executive Director, Chief Scientific Officer, Chairman of the Nomination Committee, Remuneration Committee Members, Authorized Representative
  • --
  • song li
  • Executive Director, Vice President of R&D
  • --
  • cong xu
  • Non-executive Directors, Remuneration Committee Members, Audit Committee Members
  • --
  • zhenping zhu
  • Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
  • --
  • Kendall A. Smith
  • Independent Non-Executive Director, Remuneration Committee Members
  • --
  • zhida yang
  • Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members, Remuneration Committee Members
  • --
  • wei zhang
  • Employee Representative Supervisor
  • --
  • miao tian
  • Auditors
  • --
  • zimeng zhao
  • Auditors
  • --
  • ruliang zhang
  • Senior Vice President, Deputy General Manager
  • --
  • qiying lu
  • Senior Vice President, Chief Medical Officer
  • --
  • zikai xiong
  • Senior Vice President
  • --
  • xiaodong gan
  • Senior Vice President
  • --
  • mei guan
  • Executive Director, Director of Investment and Financing Strategy Department, Joint Company Secretary, Board Secretary
  • --
  • jianwei li
  • Joint Company Secretary, Authorized Representative
  • --
Heat List
HK
Overall
Symbol
Price
% Chg

No Data

Investment Theme Pharmaceutical Companies
Pharmaceutical Companies
Intraday-0.05%